271 results on '"Iwama, Eiji"'
Search Results
2. Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
3. Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutations
4. Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors
5. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
6. Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers
7. Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review
8. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas
9. Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib
10. Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer.
11. Effect of Composite Formation with Various Metals on Improving the Anode Performance of Hematite for Na-Ion Batteries.
12. YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells
13. O7-2 A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC
14. Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutations
15. Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis
16. Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer
17. Corrigendum to “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation–positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy” [Lung Cancer 177 (2023) 44–50]
18. Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFRactivating mutations
19. MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma
20. Regulation of PD-L1 expression in non–small cell lung cancer by interleukin-1β
21. Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
22. Supplementary Figure S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
23. Supplementary Table S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
24. Afatinib-Induced Bronchiolitis Obliterans
25. Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non–small-cell lung cancer
26. Cyclability enhancement of CeO2/Sb2O3 composite electrode via ternary Na-storage reactions
27. Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma
28. MicroRNA-326 Negatively Regulates CD155 Expression in Lung Adenocarcinoma
29. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer
30. Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma.
31. Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations
32. A Phase II Study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutation-Positive NSCLC in Whom Systemic Disease (T790M-Negative) Progressed after Treatment with First- Or Second-Generation EGFR TKIS and Platinum-Based Chemotherapy
33. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
34. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement–positive non–small cell lung cancer treated with alectinib
35. α-Fe2O3 conversion anodes with improved Na-Storage properties by Sb addition
36. Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement
37. Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone
38. Abstract 1918: Coxsackievirus A11 elicits a potent oncolytic activity in human malignant pleural mesothelioma via ICAM-1 receptor
39. Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer
40. Optimal next-generation sequencing (NGS) panel for estimating tumor mutation burden (TMB) and its clinical implication for non-small cell lung cancer (NSCLC).
41. Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).
42. Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer
43. Cancer-Related PRUNE2 Protein Is Associated with Nucleotides and Is Highly Expressed in Mature Nerve Tissues
44. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation
45. Retrospective Analysis of the Effect of Chemotherapy in Patients with Recurrent NSCLC After the First Line Chemoradiotherapy or Curative Radiotherapy: PS019
46. Which Do NSCLC Patients with EGFR Mutation Prefer as a First-Line Therapy, EGFR-TKI or Chemotherapy? A Vignettes Study (LOGIK0903): OS096
47. Bone Metastases are more Frequent and Multiple in EGFR Mutation Positive NSCLC Patients: OS075
48. Osimertinib failure followed by successful treatment of afatinib in a patient with compound uncommon, G719S and V834L mutations
49. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors
50. Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.